Compare QUIK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | FHTX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.7M | 173.4M |
| IPO Year | 1997 | 2020 |
| Metric | QUIK | FHTX |
|---|---|---|
| Price | $9.36 | $1.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $23.00 | $4.17 |
| AVG Volume (30 Days) | 184.2K | ★ 1.2M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | $20,112,000.00 | ★ $30,909,000.00 |
| Revenue This Year | $73.33 | N/A |
| Revenue Next Year | $16.92 | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $5.28 | $1.79 |
| 52 Week High | $24.33 | $7.61 |
| Indicator | QUIK | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 16.46 |
| Support Level | $8.72 | $1.79 |
| Resistance Level | $10.14 | $5.35 |
| Average True Range (ATR) | 0.45 | 0.25 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 13.75 | 4.66 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.